Compare · ABBV vs KALV
ABBV vs KALV
Side-by-side comparison of AbbVie Inc. (ABBV) and KalVista Pharmaceuticals Inc. (KALV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and KALV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $383.62B, about 267.4x KALV ($1.43B).
- Over the past year, ABBV is up 15.9% and KALV is up 98.9% - KALV leads by 83.0 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 17 for KALV).
- ABBV has more recent analyst coverage (25 ratings vs 8 for KALV).
- Company
- AbbVie Inc.
- KalVista Pharmaceuticals Inc.
- Price
- $217.14+0.78%
- $26.95-0.02%
- Market cap
- $383.62B
- $1.43B
- 1M return
- +4.28%
- +0.99%
- 1Y return
- +15.90%
- +98.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2015
- News (4w)
- 23
- 17
- Recent ratings
- 25
- 8
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.
Latest ABBV
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Latest KALV
- Amendment: SEC Form SC 14D9/A filed by KalVista Pharmaceuticals Inc.
- CHIEF DEVELOPMENT OFFICER Yea Christopher exercised 33,800 shares at a strike of $7.07 and sold $905,225 worth of shares (33,800 units at $26.78) (SEC Form 4)
- KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
- Chief Commercial Officer Sweeny Nicole sold $39,872 worth of shares (1,489 units at $26.78) and converted options into 5,000 shares, increasing direct ownership by 6% to 59,291 units (SEC Form 4) to cover withholding tax
- CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $59,955 worth of shares (2,239 units at $26.78), increasing direct ownership by 2% to 150,260 units (SEC Form 4) to satisfy tax liability
- CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,125 shares and sold $52,645 worth of shares (1,966 units at $26.78), increasing direct ownership by 0.51% to 229,918 units (SEC Form 4) (tax liability)
- CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $292,646 worth of shares (10,926 units at $26.78), increasing direct ownership by 3% to 479,989 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Sweeny Nicole converted options into 6,250 shares and sold $49,846 worth of shares (1,861 units at $26.78), increasing direct ownership by 9% to 55,780 units (SEC Form 4) to satisfy tax liability
- CHIEF DEVELOPMENT OFFICER Yea Christopher sold $63,158 worth of shares (2,358 units at $26.78) and converted options into 3,750 shares, increasing direct ownership by 0.61% to 228,759 units (SEC Form 4) to satisfy withholding obligation
- CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 6,250 shares and sold $71,916 worth of shares (2,685 units at $26.78), increasing direct ownership by 2% to 147,499 units (SEC Form 4) to cover withholding tax